Dechert Recognized Among Top Law Firms for Life Sciences M&A Deals by Mergermarket
Global specialist law firm Dechert LLP has been ranked among the top law firms for life sciences M&A deals in North America and Europe in 2015 by Mergermarket.
Dechert was ranked among the top law firms for total volume of life sciences and healthcare M&A deals in North America and ranked among the top law firms for total volume of pharma, medical and biotech M&A deals in Europe in the full year editions of Deal Drivers Americas and Deal Drivers EMEA.
“Dechert’s work in this sector is a priority for the firm. We were particularly active in domestic and cross-border life sciences M&A transactions on both sides of the Atlantic as the industry witnessed record levels of pipeline replenishment and consolidation,” said David Schulman, co-chair of the firm’s life sciences practice. “This recognition is a testament to the hard work conducted by our global team of life sciences lawyers over the past year.”
Life sciences M&A highlights from 2015 include representing Celgene Corporation, a global biopharmaceutical company, in two major transactions: the acquisition of a 10% stake in Juno Therapeutics, Inc. as part of a 10-year collaboration for the development and commercialization of immunotherapies worth approximately US$1 billion (which was recently recognized as Impact Deal of the Year by LMG Life Sciences); and Celgene’s US$485 million acquisition of Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery. Dechert also advised long-time client MWI Veterinary Supply, Inc., the leading animal health distribution company in the United States, on its sale to AmerisourceBergen Corporation for US$2.5 billion. In addition, the firm provided antitrust and regulatory counsel to CVS Health in connection with its US$12.7 billion purchase of pharmacy services giant Omnicare Inc.
Other life science M&A highlights from 2015 include:
- Dechert Advises Cathay Capital on its Investment in Cenexi Group
- Dechert Advises Harvard Drug in US$1.12 Billion Sale to Cardinal Health
- Dechert Advises AM-Pharma and its Shareholders on US$600 Million Pfizer Transaction
- Dechert Represents Select Medical in US$1.055 Billion Concentra Acquisition via Joint Venture with Welsh Carson
- Dechert Advises XO1 on its Sale to Janssen Pharmaceuticals
- Dechert Advises GSK in Exchange of Strategic Assets with Novartis
- Dechert Advises Biota Pharmaceuticals in Cross-Border Acquisition of Anaconda Pharma
- Dechert Advises Shareholders of Trophos in Buy Back by Roche
About Dechert
Dechert is a global specialist law firm with a deep bench of experts focused on sectors with the greatest complexities and highest regulatory demands. We deliver practical commercial insight and judgment to our clients’ most important matters. Nothing stands in the way of giving clients the best of the firm’s entrepreneurial energy and seamless collaboration in a way that is distinctively Dechert.
